Crescent Biopharma (CBIO) Stock Price, News & Analysis

Company Overview

Crescent Biopharma, Inc. (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company focused on developing innovative medicines for serious diseases, with an emphasis on oncology.

The company’s activities include drug discovery, preclinical research, clinical development and regulatory advancement of investigational therapies. Crescent Biopharma is focused on advancing its development pipeline and does not appear to have a broad portfolio of marketed products.

Publicly available information about the company’s specific drug candidates, geographic operations and leadership is limited.

Key Stats

• Today's Range: $14.07 to $15.28
• 50-Day Range: $13.49 to $20.88
• 52-Week Range: $8.72 to $27.41
• Volume: 347,149 shs
• Average Volume: 561,674 shs
• Market Capitalization: $553.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.40
• Consensus Rating: Buy

Crescent Biopharma Stock Analysis - MarketRank™

Crescent Biopharma scored higher than 60% of companies evaluated by MarketBeat, and ranked 227th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Crescent Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Crescent Biopharma has a consensus price target of $32.40, representing about 117.3% upside from its current price of $14.91.

Amount of Analyst Coverage

Crescent Biopharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Crescent Biopharma are expected to decrease in the coming year, from ($2.93) to ($3.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Crescent Biopharma is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Crescent Biopharma is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Crescent Biopharma has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.11% of the float of Crescent Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Crescent Biopharma has a short interest ratio ("days to cover") of 6.85.

Change versus previous month

Short interest in Crescent Biopharma has recently increased by 40.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Crescent Biopharma does not currently pay a dividend.

Dividend Growth

Crescent Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.44

News Sentiment

Crescent Biopharma has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Crescent Biopharma this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for CBIO on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Crescent Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Crescent Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $285,501.00 in company stock.

Percentage Held by Insiders

24.84% of the stock of Crescent Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBIO
• Previous Symbol: NASDAQ:CBIO
• CIK: 1253689
• Web: www.crescentbiopharma.com
• Phone: (617) 430-5595
• Fax: 336-480-2107
• Employees: 44
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Crescent Biopharma: $32.40
• High Price Target: $36.00
• Low Price Target: $27.00
• Potential Upside/Downside: +117.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$153.94 million
• Net Margins: N/A
• Pretax Margin: -1,372.75%
• Return on Equity: -101.50%
• Return on Assets: -86.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.66
• Quick Ratio: 9.66

Sales & Book Value

• Annual Sales: $10.84 million
• Price / Sales: 51.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.32 per share
• Price / Book: 1.04

Miscellaneous

• Outstanding Shares: 37,140,000
• Free Float: 27,917,000
• Market Cap: $553.76 million
• Optionable: No Data
• Beta: 1.27